Hims & Hers stock is full of noise, but what's the signal for investors?
Eli Lilly just gave investors several reasons to cheer.
Hims & Hers Health, Inc. HIMS has emerged as a transformative player in the personalized healthcare market, showcasing robust growth in 2024. Shares of the company have risen 43% in the past month, significantly...
Leerink analysts said the Ro-Lilly partnership is likely to cause volatility for Hims & Hers shares.
Hims & Hers, Alcoa, Vicor, and Stride crushed earnings with massive EPS beats. See what’s driving their growth and future potential.
Amazon's strategic healthcare expansion leverages technology and logistics for a potentially transformative impact on patient care and market dynamics.
Discover two telehealth stocks, Hims & Hers (HIMS) and Teladoc (TDOC), poised to benefit from Trump's FDA nominee, Dr. Marty Makary, a telemedicine advocate.
Teladoc Health, Inc. TDOC shares have returned 59.4% in the past three months, outperforming the industry and the S&P 500 Index. Over this timeframe, the industry and the S&P 500 Index have declined 11.7%...
Here's why Eli Lilly, Pfizer, and AstraZeneca are biotech stocks worth considering, with strong pipelines and growth potential beyond vaccines.
Shares of Hims & Hers were on fire Monday because the FDA's new leader seems to be a fan of the company's business model.